|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Cure_Vac_AG
gptkb:Tx_Cell_SA
|
|
gptkbp:ceo
|
gptkb:Sandy_Macrae
|
|
gptkbp:clinical_trial
|
gptkb:SB-318
Phase 1
Phase 2
Phase 3
ST-400
TX200
SB-913
|
|
gptkbp:collaboration
|
gptkb:UCLA
gptkb:Stanford_University
gptkb:University_of_California,_Berkeley
gptkb:University_of_Pennsylvania
|
|
gptkbp:employees
|
~200
|
|
gptkbp:focus
|
gptkb:gene_therapy
gptkb:cystic_fibrosis
gptkb:sickle_cell_disease
gptkb:HIV
gptkb:Duchenne_muscular_dystrophy
gptkb:Fuchsia
gptkb:muscular_dystrophy
gptkb:anemia
gptkb:Cell
gptkb:neurodegenerative_diseases
gptkb:multiple_sclerosis
genome editing
|
|
gptkbp:focus_area
|
gptkb:Oncology
rare diseases
neurological disorders
infectious diseases
|
|
gptkbp:founded
|
gptkb:1995
|
|
gptkbp:founder
|
gptkb:Edward_Lanphier
|
|
gptkbp:headquarters
|
gptkb:Richmond,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sangamo Therapeutics
|
|
gptkbp:invention
|
Cell Therapy Methods
Gene Therapy Methods
Zinc Finger Technology
|
|
gptkbp:investment
|
$100 million (2021)
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Gilead_Sciences
gptkb:Novartis
|
|
gptkbp:revenue
|
$20 million (2020)
|
|
gptkbp:stock_symbol
|
gptkb:SGMO
|
|
gptkbp:technology
|
gptkb:Zinc_Finger_Nucleases
AAV vectors
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.sangamo.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
|
|
gptkbp:bfsLayer
|
3
|